Please login to the form below

ribociclib

This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.

Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO

Novartis also presented data from the phase 3 MONALEESA-3 trial analysing the efficacy and safety of Kisqali (ribociclib) in combination with fulvestrant in postmenopausal women with HR-positive/HER2-negative

Latest news

Novartis' Kisqali shows long-term improvements in breast cancer patients

Exploratory analysis of OS results for Kisqali (ribociclib) plus fulvestrant as a first- or second-line treatment compared to fulvestrant alone in this patient population found that the Kisqali combination continued
Novartis weathers the COVID-19 storm in Q3, lifts outlook

In addition, sales of the company’s plaque psoriasis treatment Cosentyx (secukinumab) increased by 7%, with its HER2-negative breast cancer therapy Kisqali (ribociclib) also growing by 50%.
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

According to NICE, Ibrance now joins two other of its approved drugs – Novartis’ Kisqali (ribociclib) and Lilly’s Verzenio (abemaciclib) - as a treatment option for patients at this stage of the
Novartis highlights emerging assets and late-stage pipeline at R&D day

It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.
Lilly boosted by survival data for key growth drug Verzenio

However, shortly after the top-line data were announced, Novartis reported results with a trial of its rival CDK4/6 inhibitor Kisqali (ribociclib) which stole some of Lilly’s thunder.

More from news
Approximately 4 fully matching, plus 35 partially matching documents found.

Latest appointments

Ipsen boosts specialty care and R&D leadership teams

East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Principal Medical Writer, MRNA/ Covid 19, Medical Communications...: Highly competitive salary

FREELANCE Associate Director - Healthcare PR - Remote or London: Superb Day Rate &Benefits

Medical Writers > Scientific Directors – Medical Communicatio...: Highly Competitive Salary, Bonus &Benefits

Scientific Director, MRNA/ Covid 19, Medical Communications, UK: Six figure salary

B2B media account director: Competitive salary

Client Services Director, MRNA/ Covid 19, Medical Communications...: Highly competitive salary

HR Manager – Recruitment/ Generalist combined role, Marketing ag...: circa £50K

AM / Senior Account Manager – Healthcare PR - London / Remote: Highly Competitive Salary, Bonus &Benefits

Vaccines writer – career opportunity to move into medcomms from ...: Highly competitive salary

Senior Account Exec > CSD – Medical Communications – UK, Lond...: Highly Competitive Salary, Bonus &Benefits

Entry Level Account Executive – Healthcare Advertising – London...: Salary TBC

PMHub

Add my company

Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs: In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?: Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:: Securing a future for telehealth with immersive market research insights...

Email:
Password:

Please login to the form below

ribociclib

COVID-19 Updates and Daily News

Featured jobs

Quick links